Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rang in aandelen #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aandeelprijs
$0.00244926
Marktkapitalisatie
$51.67K
Verandering (1 dag)
5.88%
Verandering (1 jaar)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Categorie

EPS voor Nuformix plc (NFX)
EPS per September 2025 TTM: $0.00
Volgens de laatste financiële rapporten en de aandelenkoers van Nuformix plc is de huidige EPS van het bedrijf (TTM) $0.00. Eind 2024 had het bedrijf een EPS van $-0.01, een daling ten opzichte van de EPS van 2023 die $0.00 bedroeg.
EPS-geschiedenis van Nuformix plc van 2014 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
2026 (TTM) 0.00 -100.00%
2025 0.00 -100.00%
2024 $-0.01 520.00%
2023 0.00 -60.00%
2022 0.00 -16.67%
2021 0.00 50.00%
2020 0.00 -57.45%
2019 0.00 -31.88%
2018 $-0.01 -23.33%
2017 $-0.01 8.43%
2016 $-0.01 0.00%
2014 0.00 0.00%
EPS van vergelijkbare bedrijven of concurrenten
Bedrijf EPS EPS-verschil Land
$3.62 -402,577.78%
DK
$15.47 -1,718,988.89%
US
$43.12 -4,791,211.11%
US
$9.62 -1,069,077.78%
BE
$2.98 -331,211.11%
AU